BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33490266)

  • 1. Identification and Verification of Molecular Subtypes with Enhanced Immune Infiltration Based on m6A Regulators in Cutaneous Melanoma.
    Lin Y; Wang S; Liu S; Lv S; Wang H; Li F
    Biomed Res Int; 2021; 2021():2769689. PubMed ID: 33490266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenomic and genomic analysis of transcriptome modulation in skin cutaneous melanoma.
    Chen W; Cheng P; Jiang J; Ren Y; Wu D; Xue D
    Aging (Albany NY); 2020 Jul; 12(13):12703-12725. PubMed ID: 32639949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Alterations of N6-Methyladenosine (m
    Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
    Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of subgroups along the glycolysis-cholesterol synthesis axis and the development of an associated prognostic risk model.
    Zhang E; Chen Y; Bao S; Hou X; Hu J; Mu OYN; Song Y; Shan L
    Hum Genomics; 2021 Aug; 15(1):53. PubMed ID: 34384498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis.
    Mo W; Ding Y; Zhao S; Zou D; Ding X
    PLoS One; 2020; 15(11):e0241924. PubMed ID: 33170908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of Prognostically Relevant Gene Signature in Melanoma.
    Gao Y; Li Y; Niu X; Wu Y; Guan X; Hong Y; Chen H; Song B
    Biomed Res Int; 2020; 2020():5323614. PubMed ID: 32462000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
    Front Immunol; 2021; 12():637933. PubMed ID: 33746977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene signature and prognostic merit of M6a regulators in colorectal cancer.
    Zhang J; Cheng X; Wang J; Huang Y; Yuan J; Guo D
    Exp Biol Med (Maywood); 2020 Sep; 245(15):1344-1354. PubMed ID: 32605475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N6-methyladenosine methylation landscape stratifies breast cancer into two subtypes with distinct immunological characteristics.
    Chen Y; Hou Y; Li S; Qin W; Zhang J
    Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13875. PubMed ID: 38797522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M6A-Related Bioinformatics Analysis Reveals a New Prognostic Risk Signature in Cutaneous Malignant Melanoma.
    Yu Q; Zhu H; Wang H; Aimaier R; Chung M; Wang Z; Li Q
    Dis Markers; 2022; 2022():8114731. PubMed ID: 35722625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of RNA methylation N6-methyladenosine regulators on malignant progression and prognosis of melanoma.
    Liu J; Zhou Z; Ma L; Li C; Lin Y; Yu T; Wei JF; Zhu L; Yao G
    Cancer Cell Int; 2021 Aug; 21(1):453. PubMed ID: 34446007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
    Han X; Liu J; Cheng G; Cui S
    Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer.
    Ma J; Yang D; Ma XX
    Aging (Albany NY); 2021 Jun; 13(12):16287-16315. PubMed ID: 34230220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic values of m6A RNA methylation regulators in uveal melanoma.
    Tang J; Wan Q; Lu J
    BMC Cancer; 2020 Jul; 20(1):674. PubMed ID: 32682400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
    Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
    Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.
    Li J; Cao J; Liang C; Deng R; Li P; Tian J
    Med Oncol; 2022 Jan; 39(4):41. PubMed ID: 35092501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.